Tag Archives: Conversion to Dementia From Prodromal Disease
Blood Test Able to Predict Alzheimer's Disease Decades Before Symptoms? (BBC News / Neurology)
Posted on August 3, 2019	by Dementia and Elderly Care News
Summary Research published in the Neurology journal claims a significant breakthrough in the development of a blood test (for plasma Aβ42/Aβ40) which may be able to predict Alzheimer's Disease onset with 94% accuracy. Due caution: "But it's important to note … Continue reading →
Posted in BBC News, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Quick Insights, Universal Interest	| Tagged Alzheimer's Disease: Diagnosis, Alzheimer's Early Screening, Amyloid, Amyloid and Tau PET, Amyloid Beta, Amyloid Beta (Aβ42 and Aβ40), Amyloid Beta Protein, Amyloid-β (Aβ), Amyloid-β Protein, BBC Health News, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood Test for Brain Amyloidosis: Validated Using Amyloid PET and CSF p-tau181/Aβ42 as Reference Standards, Blood Tests, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer's Disease, Brain Imaging, Brain Research, Case Finding, Conversion to Dementia From Prodromal Disease, Dementia Diagnosis, Dementia Innovation, Dementia Research, Dementia Screening, Department of Neurology: Washington University, Diagnosis, Diagnosis of Alzheimer's Disease, Diagnostic Imaging, Division of Biostatistics: Washington University, Drug Development for Alzheimer's Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Hope Center for Neurological Disorders: Washington University, Knight Alzheimer's Disease Research Center: Washington University, Mallinckrodt Institute of Radiology: Washington University, Neurology (Journal), Non-Invasive Biomarkers, Plasma Biomarkers, Plasma β-Amyloid 42/40, Plasma Protein Markers of MRI Measures in Asymptomatic Individuals, Preclinical Alzheimer's Disease, Preclinical Biomarkers in Alzheimer's Disease, Predictive Ability (of Tests), Prodromal Alzheimer's Disease, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Rapid Screening, Recruitment Onto Dementia Clinical Trials, SAP (Protein), SAP: Serum Amyloid Protein, Screening, Screening for Dementia, Washington University School of Medicine	| Leave a comment
Summary of Recent Progress in Alzheimer's Disease Prevention Trials (CTAD / JPAD)
Summary The following article summarises a round-up of present understanding and developments reflected in current and planned prevention trials, as discussed at a EU / US / Clinical Trials in Alzheimer's Disease (CTAD) Task Force meeting, as of December 2016-7. … Continue reading →
Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Quick Insights	| Tagged Accelerating Alzheimer's Research and Drug Development, Alzheimer's Disease Co-operative Study - Activities of Daily Living Scale (ADCS-ADL), Alzheimer's Disease Prevention Trials, Alzheimer's Prevention Initiative (API), Alzheimer's Prevention Initiative Study, Alzheimer's Therapeutic Research Institute (ATRI), Amsterdam IADL Questionnaire, Amyloid and Tau Imaging, Amyloid and Tau PET, Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) Study, Banner Alzheimer's Institute (Arizona), Biological Markers, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer's Disease, Brigham and Women's Hospital, Canada, CHU Toulouse (France), Cognitive Function Instrument, Cognitive Outcome Measures, Cogstate iPad C3 Battery, Collaboration for Alzheimer's Prevention (CAP), Composite Measures (sic Cognitive Composites), Conversion to Dementia From Prodromal Disease, Dementia Prevention, Dementia Research and Drug Development, Dementia Risk Prevention, Dementia Risk Reduction and Prevention, Denali Therapeutics (South San Francisco), Department of Epidemiology and Public Health: CHU Toulouse, DIAN-TU Study, DIAN-TU Trial, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), Dominantly Inherited Alzheimer's Network Trials Unit (DIAN-TU), Drug Development for Alzheimer's Disease, Drug-Development Pipeline, EU/US/Clinical Trials in Alzheimer's Disease (CTAD) Task Force, EU/US/Clinical Trials in Alzheimer's Disease (CTAD) Task Force (December 2016 Meeting), European Medicines Agency, Everyday Cognition (E-Cog) Scale, F-31073 (Toulouse), F. Hoffmann-LaRoche Ltd (Basel), France, Free and Cued Selective Reminding Test (FCSRT), Functional Activities Questionnaire (FAQ), Gerontopole Toulouse: Toulouse University Hospital, Global R&D Partners LLC (San Diego), Harvard Medical School, Imaging, Inc. (New York), Informant-Reported Outcome Measures, Innovation Infrastructure, Johns Hopkins University School of Medicine Baltimore, Journal of Prevention of Alzheimer's Disease (JPAD), Keck School of Medicine: University of Southern California, Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) Study, McGill University, Molecular Imaging; Mild Behavioral Impairment, Multi-Domain Alzheimer's Prevention Trial (MAPT), National Institutes of Health's Accelerating Medicines Partnership (AMP), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neurology (FDA), Next Generation (NexGen) Prevention Trial, NIH Toolbox Cognition Battery (NIHTB-CB), Non-Invasive Biomarkers, Outcome Measures, Participation in Research, Patient Reported Outcome Measures, Pentara Corporation (Salt Lake City), PET, Pfizer, Plasma Biomarkers, Preclinical Alzheimer's Disease, Preclinical Alzheimer's Cognitive Composite (PACC), Preclinical Biomarkers and Dementia, Preclinical Biomarkers in Alzheimer's Disease, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Prevention, Prevention Agenda, Prevention Agenda Linking Dementia and Other Non-Communicable Diseases, Prevention Approaches, Prodromal Alzheimer's Disease, Promisary Science, Recruitment and Retention, Regulation and Drug Development For Early-Stage Alzheimer's Disease, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Research Promotion, Sharing Knowledge and Information, Slowing Progression of Disease (Stabilisation), Switzerland, Tau PET, Technology and Infrastructure Development, TOMMORROW Study, UMR1027 Inserm, United States, University College London, University Hospital of Montpellier, University of Southern California, University of Toulouse III, USA, Washington University School of Medicine	| Leave a comment
Investigations Into the Early Signs, Symptoms and Family Experiences of Alzheimer's Disease (BMJ Open / International Psychogeriatrics)
Summary A literature review analyses the sequence / timing of the early signs and symptoms of Alzheimer's Disease. The authors distinguish between the early signs of late-onset Alzheimer's Disease (LOAD) and those of early-onset Alzheimer's Disease (EOAD). Full Text Link … Continue reading →
Posted in Community Care, Depression, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), International, Mental Health, Models of Dementia Care, Quick Insights, Systematic Reviews, UK, Universal Interest	| Tagged Aberrant Motor Behaviour, Acalculia, Agitation, Alexia, Anomia, Anosognosia, Anxiety, Apathy, Australia, BMJ Open, BMJ Publishing Group Ltd, Box Hill Hospital (Victoria), Cognitive Impairment, Conversion to Dementia From Prodromal Disease, Disinhibition, Early Detection of Preclinical Disease, Early Signs and Symptoms of Alzheimer's Disease, Early-Onset Alzheimer's Disease (EOAD), Early-Onset Dementia, Eastern Cognitive Disorders Clinic: Box Hill Hospital, Experiences, Experiences of the Transition to Dementia, Family and Caregiver Experiences, Family Members' Experiences of Pre-Diagnostic Phase of Dementia, Hallucination, Initial Onset and Diagnosis, Institute for Health Research: University of Bedfordshire, International Psychogeriatrics, Irritability, Late Onset Dementia, Late-Onset Alzheimer's Disease, Late-Onset Alzheimer's Disease (LOAD), Melbourne School of Psychological Sciences: University of Melbourne, Neuroscience Department: Box Hill Hospital, Olfactory Disturbances, Patient and Carer Experiences, Patient Experiences, Pre-Diagnostic Phase of Dementia, Preclinical Alzheimer's Disease, Preclinical Indicators in Alzheimer's Disease, Preclinical Phase of Dementia, Prodromal Alzheimer's Disease, School of Life Sciences: University of Hull, Signs and Symptoms of Alzheimer's Disease, University of Bedfordshire, University of Hull, University of Melbourne, Weight Loss, Young Onset Dementia (YOD), Young-Onset Dementia	| Leave a comment
Blood Test for Pre-Symptomatic Alzheimer's Disease Likely to Arrive Soon? (BBC News / Nature)
Summary A blood test developed by researchers in Australia and Japan appears to be able to predict the risk of developing Alzheimer's Disease, with 90% accuracy. Detection of amyloid beta in the blood may be taken as a biomarker for … Continue reading →
Posted in BBC News, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Quick Insights, Universal Interest	| Tagged Alzheimer's Disease, Amyloid Beta, Amyloid-β (Aβ), Austin Health: Australia, Australia, ß-amyloid, BBC Health News, Beta-Amyloid, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer's Disease, Center for Development of Advanced Medicine for Dementia:: National Center for Geriatrics and Gerontology (Japan), Conversion to Dementia From Prodromal Disease, CSIRO (Brisbane), Edith Cowan University: Western Australia, Florey Institute: University of Melbourne, Health and Biosecurity: CSIRO (Brisbane), Japan, Koichi Tanaka Mass Spectrometry Research Laboratory: Shimadzu Corporation, Koichi Tanaka Mass Spectrometry Research Laboratory: Shimadzu Corporation (Kyoto), Laboratory of Neuropathology and Neuroscience: University of Tokyo, National Center for Geriatrics and Gerontology (Japan), Nature, Non-Invasive Biomarkers, Plasma Amyloid-β Biomarkers for Alzheimer's Disease, Plasma Biomarkers, Preclinical Biomarkers in Alzheimer's Disease, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Shimadzu Corporation, Shimadzu Corporation (Kyoto), Tokyo Metropolitan Institute of Gerontology, University of Melbourne, University of Tokyo	| Leave a comment
Nutritional Intervention to Slow Dementia Progression?: Evidence Still Unclear on Nutricia's Souvenaid Drink (BBC News / Lancet Neurology / NHS Choices)
Posted on November 3, 2017	by Dementia and Elderly Care News
Summary A LipiDiDiet trial investigated the effects of Fortasyn Connect on cognitive decline (and related measures) in the early stages of Alzheimer's Disease. This small trial indicates that Nutricia's nutrient drink Souvenaid has no significant effect on the rate of … Continue reading →
Posted in BBC News, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Non-Pharmacological Treatments, Nutrition, Pharmacological Treatments, Quick Insights, Universal Interest	| Tagged Alzheimer Center Limburg: University of Maastricht, Alzheimer Center: VU University Medical Center, Alzheimer's and Dementia: The Journal of the Alzheimer's Association, Alzheimer's and Dementia: Translational Research and Clinical Interventions (TRCI), Alzheimer's and Dementia (Journal), Amsterdam Neuroscience: VU University Medical Center, BBC Health News, Behind the Headlines, Care Sciences and Society: Karolinska Institute, Clinical Neurochemistry Laboratory: Sahlgrenska University Hospital, Clinical Trials Unit: Karolinska University Hospital, Cognitive Impairment, Conversion to Dementia From Prodromal Disease, Department of Clinical Geriatrics: Karolinska Institute, Department of Experimental Neurology: Saarland University, Department of Geriatric Medicine: Karolinska University Hospital, Department of Neurobiology: Karolinska Institute, Department of Neurology: Kuopio University Hospital, Department of Neurology: University of Eastern Finland, Department of Neurology: VU University Medical Center, Department of Psychiatry and Neurochemistry: Sahlgrenska Academy at University of Gothenburg, Department of Psychiatry and Neuropsychology: University of Maastricht, European Commission 7th Framework Programme, European Community's Seventh Framework Programme, Fatty Acids, Finland, Fortasyn Connect, German Institute for Dementia Prevention (DIDP), Germany, Improving Nutritional Care, Institute of Clinical Medicine: University of Eastern Finland, Institute of Neuroscience and Physiology: Sahlgrenska Academy at University of Gothenburg, Karolinska Institutet, Karolinska Institutet (Stockholm), Karolinska University Hospital, Kuopio University Hospital, Lancet Neurology, LipiDiDiet Trial, Medical Faculty: Saarland University, Netherlands, Neuneuropsychological Test Battery (NTB), NeuroCenter Kuopio University Hospital, NL-ENIGMA Trial, Nutricia Advanced Medical Nutrition, Nutricia's Souvenaid Drink, Nutrients, Nutrition and Dementia, Nutrition Support, Nutritional Approaches to Slowing or Arresting Cognitive Impairment / Dementia, Nutritional Interventions, Nutritional Supplementation, Oral Nutritional Supplements, Pentara Corporation (Salt Lake City), Preclinical Alzheimer's Disease, Preclinical Phase of Dementia, Prodromal Alzheimer's Disease, Saarland University (Homburg), Sahlgrenska Academy: University of Gothenburg, Sahlgrenska University Hospital, Souvenaid Drink (Nutricia), Sweden, University of Eastern Finland, University of Gothenburg, University of Maastricht, USA, Vitamins, VU University Medical Center	| Leave a comment
Earlier Diagnosis Research: the Deep and Frequent Phenotyping Study (BBC News / GtR)
Posted on June 28, 2017	by Dementia and Elderly Care News
Summary The Deep and Frequent Phenotyping Study aims to discover new ways of diagnosing dementia, ideally decades before the symptoms become apparent in order to give future drug treatments the best chance of working. The Deep and Frequent Phenotyping Study … Continue reading →
Posted in Alzheimer's Society, BBC News, Commissioning, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Mental Health, Models of Dementia Care, National, NIHR, Quick Insights, UK, Universal Interest	| Tagged Ageing Population, Alterations in Movement and Walking ("Gait") Assessments, Alzheimer's Disease: Early Detection by Brain Scan, Alzheimer's Disease Biomarkers, Amnestic Mild Cognitive Impairment (a-MCI), Amnestic Mild Cognitive Impairment (aMCI), Applications of Big Data, BBC Radio, BBC Radio 4, BBC's World At One Programme, Big Data Analytics, Big Data Funding and Research, Biomarker Assessments in Alzheimer's Disease, Biomarker Assessments in Alzheimer's Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Biomarkers Research Programmes, Blood and Urine Biomarkers, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer's Disease, Brain Scans, Cambridge Neuropsychological Test Automated Battery (CANTAB), Cerebrospinal Fluid (CSF) Biomarkers, Clinical Assessments, Cognitive Assessments / Screening Tools, Conversion to Dementia From Prodromal Disease, CSF Biomarkers, Deep and Frequent Phenotyping Study, Deep and Frequent Phenotyping Study (DFP), Deep and Frequent Phenotyping; Combinatorial Biomarkers of Dementia, Dementia Research, Dementia Research Funding, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, DFP Study Team, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DPUK: Dementias Platform UK, Drug Trials Failure Rate, Early Detection of Alzheimer's Disease, Early Detection of Preclinical Disease, EEG: Electroencephalography, Effectiveness of Early Detection and Treatment, Electroencephalogram (EEG) Brain Scans, Electroencephalography (EEG), Gait and Cognition, Gait Changes, Gateway to Research (GtR), Global Dementia Research, Global Leadership, Hypothetical Prodromes of Dementia, Imanova, Imperial College London, Join Dementia Research, Join Dementia Research: Clinical Trials Matchmaker Service, Join Dementia Research: Recruitment Onto Dementia Studies, Kings College London, Magnetic Resonance Imaging (MRI) Scan, Magnetoencephalography (MEG), Medical Research Council (MRC), Medical Research Council (UK), National Institute of Health Research (NIHR), Neurobiology of Aging (Journal), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Newcastle University, Non-Invasive Biomarkers, Ocular Manifestations in Neurodegenerative Diseases, Open Data and Big Data, Ophthalmological Assessments, Participation in Research, Participation in Research Studies, Partnership and Collaboration, Patient and Public Participation, PharmaCog Consortium, Positron Emission Tomography (PET), Pre-Clinical Genotype-Phenotype Predictors of Alzheimer's Disease, Prodromal Alzheimer's Disease, Professor Clare Mackay: Imaging Neuroscience at the University of Oxford, Professor Lynn Rochester: Clinical Ageing Research Unit at Newcastle University, Professor Simon Lovestone: Lead Researcher and Professor of Translational Neuroscience at University of Oxford, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Proteomic Analysis, Proteomics, Public Participation in Research, Publicly-Funded UK Big Data Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Funding, Retina as Early Biomarker of Neurodegeneration, Retinal Biomarkers, Retinal Changes as Surrogate Biomarker for Alzheimer's Disease, Retinal Ganglion Cells (RGCs), Retinal Manifestations of Alzheimer's Disease, Screening Tools for Amnestic Mild Cognitive Impairment (a-MCI), Surrogate Biomarkers of Neurodegeneration, Translational Research, University College London, University of Cambridge, University of Edinburgh, University of Manchester, University of Oxford, Volunteers, Walking Pattern (Gait), Wearable Devices, Wearables (Technology)	| Leave a comment
Deep and Frequent Phenotyping Study: Dementia Early Detection and Biomarkers Research Programme (MRC / NIHR)
Posted on August 22, 2016	by Dementia and Elderly Care News
Summary The Deep and Frequent Phenotyping Study will explore improvements in biomarker research and the development of tests to detect Alzheimer's Disease early on. This research programme will be funded by the National Institute of Health Research (NIHR) and the … Continue reading →
Posted in Alzheimer's Society, Charitable Bodies, Commissioning, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, National, NIHR, Quick Insights, UK, Universal Interest	| Tagged Alterations in Movement and Walking ("Gait") Assessments, Alzheimer's Disease: Early Detection by Brain Scan, Alzheimer's Disease Biomarkers, Aridhia, AstraZeneca / MedImmune, Berry Consultants, Biomarker Assessments in Alzheimer's Disease, Biomarker Assessments in Alzheimer's Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Biomarkers Research Programmes, Blood and Urine Biomarkers, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer's Disease, Brain Scans, Cambridge Cognition, Cerebrospinal Fluid (CSF) Biomarkers, Clinical Assessments, Cognitive Assessments / Screening Tools, Conversion to Dementia From Prodromal Disease, CSF Biomarkers, Deep and Frequent Phenotyping Study, Dementia Research, Dementia Research Funding, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DPUK: Dementias Platform UK, Dr Rob Buckle: Director of Science Programmes at MRC, Drug Trials Failure Rate, Early Detection of Alzheimer's Disease, Early Detection of Preclinical Disease, EEG: Electroencephalography, Effectiveness of Early Detection and Treatment, Electroencephalogram (EEG) Brain Scans, Electroencephalography (EEG), Exprodo, Gait and Cognition, Gait Changes, Global Dementia Research, Global Leadership, Hypothetical Prodromes of Dementia, Imanova, Imperial College London, IXICO, Kings College London, Magnetic Resonance Imaging (MRI) Scan, Magnetoencephalography (MEG), Medical Research Council (MRC), Medical Research Council (UK), National Institute of Health Research (NIHR), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Newcastle University, Non-Invasive Biomarkers, Ocular Manifestations in Neurodegenerative Diseases, Ophthalmological Assessments, Optos, Participation in Research, Participation in Research Studies, Partnership and Collaboration, Patient and Public Participation, Positron Emission Tomography (PET), Pre-Clinical Genotype-Phenotype Predictors of Alzheimer's Disease, Prodromal Alzheimer's Disease, Professor Chris Whitty: Chief Scientific Adviser at Department of Health, Professor Simon Lovestone: Lead Researcher and Professor of Translational Neuroscience at University of Oxford, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Proteomic Analysis, Proteomics, Public Participation in Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Funding, Retina as Early Biomarker of Neurodegeneration, Retinal Biomarkers, Retinal Changes as Surrogate Biomarker for Alzheimer's Disease, Retinal Ganglion Cells (RGCs), Retinal Manifestations of Alzheimer's Disease, Sage Bionetworks, Surrogate Biomarkers of Neurodegeneration, Translational Research, TrialSpark, University College London, University of Cambridge, University of Edinburgh, University of Manchester, University of Oxford, Volunteers, Walking Pattern (Gait), Wearable Devices, Wearables (Technology), West London Mental Health Trust / Imperial College London	| 1 Comment